# US 2016/0354375 A1 · CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES SUCH AS TAUOPATHIES

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0354375 A1
- Document ID: US20160354375A1
- Status: Published application
- Kind: A1
- Application number: 15/171,582
- Filed: 2016-06-02
- Published: 2016-12-08
- Earliest claimed: 2010-12-14
- Assignees: Electrophoretics Limited
- Applicants: Electrophoretics Limited
- Inventors: Joseph M. Sheridan; Jonathan R. Heal; William D.O. Hamilton; Ian Pike
- Web page: https://patentgrep.com/patent/US20160354375A1

## CPC

- A61K 31/517: ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A61K 31/397: having four-membered rings, e.g. azetidine
- A61K 31/4045: Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
- A61K 31/4192: 1,2,3-Triazoles
- A61K 31/437: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61K 31/444: containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/53: having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine (melarsoprol A61K31/555 {; with four nitrogen atoms A61K31/495})
- A61K 31/55: having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 21/02: Muscle relaxants, e.g. for tetanus or cramps
- A61P 21/04: for myasthenia gravis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 39/02: Antidotes
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 209/42: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D 277/68: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 403/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 405/04: directly linked by a ring-member-to-ring-member bond
- C07D 405/12: linked by a chain containing hetero atoms as chain links
- C07D 407/12: linked by a chain containing hetero atoms as chain links
- C07D 413/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 413/14: containing three or more hetero rings
- C07D 471/04: Ortho-condensed systems
- C07D 487/04: Ortho-condensed systems
- C07D 487/14: Ortho-condensed systems
- C07D 495/14: Ortho-condensed systems
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The invention relates to pharmaceutical compositions comprising casein kinase 1 delta (CK1δ) and to the use of said inhibitors in the treatment of neurodegenerative disorders such as Alzheimer's disease.

## Claims

### Claim at position 1

1-29. (canceled)

### Claim 30

A method of treating a neurodegenerative disorder in a subject, comprising administering an effective amount of a casein kinase 1 delta (ck1δ) inhibitor compound of formula (IC), or a pharmaceutically acceptable salt or solvate thereof:
wherein
“Het C” represents pyridinyl, pyrimidinyl or quinazolinyl;
Xc and Yc independently represent a bond or NH;
R1c and R2c independently represent phenyl, benzodioxinyl, pyridinyl, pyrazol-4-yl, thiophenyl or benzoxazolyl, wherein R1c and R2c may be substituted by one or more R4c groups;
R4c represents selected from hydroxyl, methoxy or —CONH2;
p represents an integer from 0 to 2;
R3c represents halogen, halo C1-6 alkyl, C1-6 alkyl, hydroxyl, C1-6 alkoxy, —S—C1-6 alkyl, —CH2—S—C1-6 S—C1-6 alkyl, —S—C2-6 alkynyl, amino, cyano, NO2, ═O, ═S, —SO2—C1-6 alkyl, —CONH2, —CO—C1-6 alkyl, —COO—C1-6 alkyl, —NH—C1-6 alkyl, —NH—CO—C1-6 alkyl, —NH—CO—CH═CH—CH2—N(Me)2, C1-6 alkyl, —CO—NH—C1-6 alkyl, —CO—NH—CH(Me)—COOH, —S—CH2—CO—N(Et)2, —NH—(CH2)2—OH, —NH—(CH2)3—OH, —NH—CH(Et)—CH2—OH, —CO—NH—(CH2)3—OH, —CH(CH2OH)2 or —S—CH2—CO—NH—CO—NH—C1-6 alkyl, aryl, C3-8 cycloalkyl, monocyclic or bicyclic heterocyclyl or a monocyclic or bicyclic heteroaryl ring system, wherein said aryl, heterocyclyl or heteroaryl groups of R3c may be optionally substituted by one or more R4c groups and wherein said C1-6 alkyl groups of R3c may be optionally substituted by one or more hydroxyl groups;
with the proviso that the compound is other than compound number 867.

### Claim 31 (depends on 30)

The method of claim 30, wherein “Het C” represents quinazolinyl.

### Claim 32 (depends on 30)

The method of claim 30, wherein one of Xc and Ycrepresents a bond and the other represents NH.

### Claim 33 (depends on 30)

The method of claim 30, wherein R1c and R2c independently represent phenyl, pyridinyl, pyrazol-4-yl or thiophenyl, wherein R1c and R2c may be substituted by one or more R4c groups selected from hydroxyl, methoxy or —CONH2.

### Claim 34 (depends on 33)

The method of claim 33, wherein R1C and R2c independently represent unsubstituted phenyl, unsubstituted pyridinyl or pyrazol-4-yl.

### Claim 35 (depends on 30)

The method of claim 30, wherein p is 0.

### Claim 36 (depends on 30)

The method of claim 30, wherein R3c represents ═O, cyano or pyridinyl.

### Claim 37 (depends on 36)

The method of claim 36, wherein p is 1 and R3c represents pyridinyl.

### Claim 38 (depends on 36)

The method of claim 36, wherein p is 2 and R3c represents ═O or cyano.

### Claim 39 (depends on 30)

The method of claim 30, wherein the compound of formula (IC) is selected from the group consisting of:
2-Phenyl-N-(pyridin-4-yl)quinazolin-4-amine (Compound 700);
N-(2,3-Dihydro-1,4-benzadioxin-6-yl)-2-phenylquinazolin-4-amine (Compound 868);
4-{([2-(Thiophen-3-yl)quinazolin-4-yl]amino}benzamide (Compound 870);
2-Phenyl-N-(1H-pyrazol-4-yl)quinazolin-4-amine (Compound 894);
2-[2-Methyl-4-(pyridin-4-yl)pyrimidin-5-yl]-1,3-benzoxazole (Compound 949);
2-[2-(Pyridin-2-yl)-4-(pyridin-4-yl)pyrimidin-5-yl]-1,3-benzoxazole (Compound 950);
5-(1,3-Benzoxazol-2-yl)-2-oxo-6-(pyridin-4-yl)-1,2-dihydropyridine-3-carbonitrile (Compound 951);
4-[(2-Phenylquinazolin-4-yl)amino]phenol (Compound 957);
N-(4-Methoxyphenyl)-2-(thiophen-2-yl)quinazolin-4-amine (Compound 973);
N-(4-Methoxyphenyl)-2-(pyridin-2-yl)quinazolin-4-amine (Compound 977);
6-Phenyl-2-(pyridin-2-yl)-N-(pyridin-4-yl)pyrimidin-4-amine (Compound 986); and 4-[(2-Phenylquinazolin-4-yl)amino]benzamide (Compound 993);
or a pharmaceutically acceptable salt or solvate thereof.

### Claim 40 (depends on 39)

The method of claim 39, wherein the compound of formula (IC) is 2-Phenyl-N-(pyridin-4-yl)quinazolin-4-amine (Compound 700) or a pharmaceutically acceptable salt or solvate thereof.

### Claim 41

The method of wherein the neurodegenerative disorder is a tauopathy,

### Claim 42 (depends on 41)

The method of claim 41, wherein the tauopathy is selected from Alzheimer's disease, frontotemporal dementia with Parkinsonism linked to chromosome 17 (FTDP-17), progressive supranuclear palsy (PSP), Pick's disease, corticobasal degeneration, multisystem atrophy (MSA), neuobasal degeneration with iron accumulation, type 1 (Hallervorden-Spatz), argyrophilic grain dementia, Down's syndrome, diffuse neurofibrillary tangles with calcification, dementia pugilistica, Gerstmann-Straussler-Scheinker disease, myotonic dystrophy, Niemann-Pick disease type C, progressive subcortical gliosis, prion protein cerebral amyloid angiopathy, tangle only dementia, postencephalitic parkinsonism, subacute sclerosing panencephalitis, Creutzfeldt-Jakob disease, amyotrophic lateral sclerosis/parkinsonism-dementia complex, non-Guamanian motor neuron disease with neurofibrillary tangles/dementia, and Parkinson's disease.

### Claim 43 (depends on 42)

The method of claim 42, wherein the tauopathy comprises Alzheimer's disease.
